Pull to refresh
Logo
Daily Brief
Following Why
The vaccine that might prevent dementia

The vaccine that might prevent dementia

New Capabilities
By Newzino Staff | |

A shingles shot shows 20% risk reduction—strongest evidence yet that vaccines can protect the aging brain

December 15th, 2025: Pfizer Publishes Methodological Critique

Overview

A shingles vaccine is showing up in dataset after dataset as a dementia preventer. Oxford researchers published results in Nature Medicine in July 2024 showing Shingrix—the recombinant shingles vaccine—cuts dementia risk by 17-20% compared to unvaccinated people. Stanford followed with a Cell study in December 2024 showing it might even slow progression in people already diagnosed, cutting dementia death risk by 29.5 percentage points. Then in April 2025, Geldsetzer's team published in Nature showing causal evidence from a natural experiment in Wales. By July 2025, GSK was presenting data at the Alzheimer's Association International Conference showing risk reductions as high as 51% in Southern California populations.

In This Story

3 People
Maxime Taquet Paul Harrison Pascal Geldsetzer
3 Orgs
UN
GSK (GlaxoSmithKline) Stanford Medicine
14 Events
4 Key Stats
17-51%
5 Scenarios
Randomized Trial Confirms AS01 Effect, New Dementia Vaccines Fast-Tracked
3 Context
HPV Vaccine and Cervical Cancer Prevention (2006-2020s)

Key Indicators

17-51%
Lower dementia risk range
Risk reduction observed across multiple studies, from 17% (Oxford Nature Medicine) to 51% (Southern California cohort at AAIC 2025)
29%
RSV vaccine effect
Arexvy (RSV vaccine with AS01) showed 29% dementia risk reduction over 18 months, matching Shingrix's effect
1.4M
UK trial participants
People enrolled in EPI-ZOSTER-110 natural experiment tracking vaccine effects from 2025-2029
29.5%
Lower dementia death risk
Reduction in dementia mortality among those already diagnosed who received the vaccine (Stanford Cell study)

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Sign Up

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

Maxime Taquet
Maxime Taquet
Associate Professor of Psychiatry, University of Oxford (Lead researcher on multiple vaccine-dementia studies)
Paul Harrison
Paul Harrison
Professor of Psychiatry, University of Oxford (Senior author on Oxford vaccine-dementia studies)
Pascal Geldsetzer
Pascal Geldsetzer
Assistant Professor of Medicine, Stanford University (Lead researcher on dementia progression study)

Organizations Involved

UN
University of Oxford Department of Psychiatry
Academic Research Institution
Status: Leading vaccine-dementia research globally

Oxford's psychiatry department is driving the vaccine-dementia connection through massive dataset analysis across multiple countries.

GSK (GlaxoSmithKline)
GSK (GlaxoSmithKline)
Multinational pharmaceutical company
Status: Actively investigating AS01 adjuvant for dementia prevention through major clinical studies

GSK developed both Shingrix and the AS01 adjuvant now showing unexpected dementia-protective properties.

Stanford Medicine
Stanford Medicine
Academic Medical Center
Status: Investigating vaccine effects on dementia progression

Stanford researchers discovered the vaccine may slow dementia progression in already-diagnosed patients.

Timeline

  1. Pfizer Publishes Methodological Critique

    Research

    Pfizer researchers challenge AS01 hypothesis in npj Vaccines, arguing data doesn't conclusively prove adjuvant's role due to incomplete vaccine brand specification in health records.

  2. GSK Presents Striking Data at AAIC 2025

    Research

    Six abstracts at Alzheimer's Association conference show 51% dementia reduction in Southern California, 33% in Medicare populations with two Shingrix doses.

  3. RSV Vaccine Shows Identical Protection

    Research

    Oxford publishes npj Vaccines study: Arexvy (RSV vaccine with AS01) reduces dementia 29% over 18 months, matching Shingrix—strongly implicating the shared adjuvant.

  4. Replication Studies Strengthen Signal

    Research

    Additional datasets from England, Australia, New Zealand confirm dementia risk reduction across populations.

  5. Geldsetzer Publishes Causal Evidence in Nature

    Research

    Stanford team's Nature paper provides causal evidence through natural experiment design, showing 20% dementia risk reduction in Welsh population.

  6. GSK Launches Massive UK Natural Experiment

    Clinical Trial

    EPI-ZOSTER-110 begins: 4-year study tracking 1.4M people aged 65-66 exploiting UK vaccine eligibility gap to test dementia protection.

  7. AS01 Adjuvant Hypothesis Emerges

    Research

    Oxford team finds RSV vaccine with same adjuvant shows identical dementia protection, pointing to AS01.

  8. Stanford Shows Therapeutic Effect

    Research

    Cell study reveals vaccine may slow progression in diagnosed patients, cutting dementia deaths 29.5%.

  9. Oxford Publishes Nature Medicine Bombshell

    Research

    Shingrix linked to 17-20% lower dementia risk over 6 years in 200,000+ patient analysis.

  10. FDA Approves Donanemab

    Regulatory

    Second anti-amyloid antibody approved, showing 35% slower decline in some patient groups.

  11. Lecanemab Gets Full FDA Approval

    Regulatory

    FDA converts lecanemab to traditional approval after trials show 27% slower cognitive decline.

  12. Lecanemab Receives FDA Accelerated Approval

    Regulatory

    First anti-amyloid drug gets accelerated approval, raising hopes for disease-modifying treatments.

  13. Zostavax Discontinued in U.S.

    Market Transition

    GSK stops distributing live Zostavax vaccine, completing transition to recombinant Shingrix.

  14. FDA Approves Shingrix

    Regulatory

    FDA approves GSK's Shingrix as superior alternative to Zostavax, with 90%+ efficacy and AS01 adjuvant.

Scenarios

1

Randomized Trial Confirms AS01 Effect, New Dementia Vaccines Fast-Tracked

Discussed by: Oxford researchers, Harvard Medical School commentary, Alzheimer's Association

A large RCT directly tests AS01-adjuvanted placebo vaccine against standard care in at-risk elderly. If it replicates the 20% risk reduction, regulatory agencies could fast-track AS01-based formulations specifically for dementia prevention within 3-4 years. GSK and competitors race to develop optimized adjuvant combinations. The mechanism—likely involving reduced neuroinflammation and enhanced clearance of pathological proteins—gets validated through biomarker studies. This opens a new prevention paradigm: vaccinating healthy 60-year-olds not against infection but against neurodegeneration itself.

2

Effect Proves Non-Causal, Healthier People Just Get More Vaccines

Discussed by: Skeptical researchers, methodological critics in published replies

Despite massive datasets, unmeasured confounding explains the association. People who seek out shingles vaccination are more health-conscious, have better healthcare access, exercise more, eat better—all dementia-protective behaviors not fully captured in electronic records. When a rigorous RCT launches, the effect vanishes. The AS01 hypothesis was correlation chasing, and the dementia field moves on to other targets. Published critiques note selection bias in who receives vaccines during transition periods between Zostavax and Shingrix.

3

Benefit Real But Modest, Becomes Standard Preventive Care Like Statins

Discussed by: Public health agencies, clinical practice guideline committees

Trials confirm a real but smaller effect—perhaps 10-12% risk reduction rather than 20%. Not a blockbuster, but meaningful at population scale when 55 million people worldwide have dementia. Shingrix becomes dual-purpose: CDC and equivalents recommend it for both shingles and cognitive health starting at age 60. Insurance covers it as preventive care. The discovery catalyzes moderate increases in vaccination rates and modest reductions in dementia incidence by 2030s, buying healthcare systems time while better treatments develop.

4

Mechanism Unlocks Entirely New Immunotherapy Class for Neurodegeneration

Discussed by: Biotech investors, neuroinflammation researchers, pharmaceutical development teams

The AS01 finding reveals that strategic immune activation in aging brains can clear toxic proteins and reduce chronic inflammation driving multiple neurodegenerative diseases. Researchers develop next-gen adjuvants and immunomodulators targeting the same pathways but optimized for CNS effects. Within a decade, "neuroimmune vaccines" treat not just Alzheimer's but Parkinson's, ALS, and other protein-misfolding diseases. The 2024 shingles-dementia discovery becomes the field's penicillin moment—an accidental finding that spawned a therapeutic revolution.

5

Pfizer Critique Proven Right, AS01 Hypothesis Collapses Under Scrutiny

Discussed by: Pfizer researchers, methodological epidemiologists, peer reviewers

Pfizer's December 2025 critique gains traction as researchers discover the AS01 signal was contaminated by unmeasured confounding and incomplete vaccine brand data. The EPI-ZOSTER-110 trial finds no significant difference between age-65 and age-66 cohorts when properly accounting for health-seeking behavior. The RSV vaccine effect disappears when Pfizer's Abrysvo (non-adjuvanted) is separated from GSK's Arexvy (AS01-adjuvanted) in cleaner datasets. The dementia-vaccine connection proves to be selection bias: healthier, more cognitively intact people get vaccinated. The field pivots back to traditional anti-amyloid and tau-targeting approaches.

Historical Context

HPV Vaccine and Cervical Cancer Prevention (2006-2020s)

2006-present

What Happened

Gardasil, approved in 2006 to prevent HPV infection and cervical cancer, initially faced skepticism about vaccinating healthy adolescents against a cancer risk years away. Early adoption was slow due to concerns about long-term effects and whether behavior change (screening) was sufficient. By 2020s, real-world data from Australia and Scandinavia showed dramatic drops in HPV infections and pre-cancerous lesions, validating prevention strategy.

Outcome

Short Term

Controversy and low uptake in first 5-7 years, especially in U.S.

Long Term

Australia on track to eliminate cervical cancer by 2035; vaccine now routine in 100+ countries.

Why It's Relevant Today

Like HPV vaccine preventing cancer, shingles vaccine preventing dementia requires proving a vaccine can stop a chronic disease years down the line—and overcoming skepticism about vaccinating healthy people against distant risks.

Statins for Primary Prevention (1987-2000s)

1987-2000s

What Happened

When statins first appeared, debate raged over giving drugs to healthy people to prevent future heart attacks. Initial trials focused on secondary prevention (people who already had heart disease). Expanding to primary prevention required large trials proving benefit outweighed risks in asymptomatic patients. Guidelines evolved slowly as evidence accumulated, with intense debate over treatment thresholds and who truly benefits.

Outcome

Short Term

Limited to high-risk patients through mid-1990s, conservative prescribing.

Long Term

Became standard preventive care for millions; estimated to prevent 20-30% of cardiovascular events in treated populations.

Why It's Relevant Today

The shingles vaccine faces the same challenge statins overcame: proving that preventive treatment of healthy people is worthwhile when benefits appear years later and require large populations to demonstrate effect.

Aspirin for Cardiovascular Prevention (1980s-2010s)

1980s-2018

What Happened

Low-dose aspirin showed promise in preventing heart attacks and strokes in observational studies and some trials starting in 1980s. It became widely recommended for primary prevention by 1990s-2000s based on perceived benefits. However, 2018-2019 large trials (ARRIVE, ASPREE, ASCEND) showed minimal benefit for primary prevention in average-risk individuals while increasing bleeding risk. Guidelines reversed, limiting recommendations to specific high-risk groups.

Outcome

Short Term

Widespread adoption for primary prevention through 2000s-2010s.

Long Term

Recommendations scaled back dramatically after rigorous RCTs; now limited to select patients.

Why It's Relevant Today

A cautionary tale: observational data suggesting preventive benefit can mislead. The vaccine-dementia link, though compelling in large datasets, requires randomized trials to avoid aspirin's fate of over-enthusiastic adoption followed by reversal.

Sources

(14)
+8
Nature Medicine Cell Harvard Health Stanford Medicine University of Oxford Alzheimer's Association Alzheimer's Disease International GSK npj Vaccines Nature University of Oxford GSK npj Vaccines npj Vaccines